Re-Pharm identifies novel anti-inflammatory activity for existing compound

Cambridge, UK – 10th February 2015 - Re-Pharm, an early-stage drug discovery and development company based on the principles of compound re-profiling, is pleased to announce the identification of RP0217 as an effective new anti-inflammatory agent.

RP0217 is an existing drug which is widely prescribed for non-inflammatory conditions. The identification of this novel anti-inflammatory activity creates the opportunity to develop new non-steroidal approaches to the treatment of a variety of disease indications.

“Re-Pharm is dedicated to re-purposing compounds to address areas of unmet medical need,” says Dr Alan Rothaul, CSO at Re-Pharm. “Our streamlined method made it possible to move efficiently through pharmacological assessment, computational chemistry work and initial testing in order to demonstrate novel anti-inflammatory activity for an existing drug.”

“We are delighted with the discovery of RP0217 and look forward to its progression through clinical trials,” says Dr Robert Scoffin, CEO at Re-Pharm. “The filing of our first patents represents a significant validation of Re-Pharm’s approach to re-profiling and I look forward to many similar future successes.”

END

Contact
Sue Peffer, Marketing Manager, sue@re-pharm.com +44 (0)1223 858890

About Re-Pharm – Smarter Drug Re-Profiling
Re-Pharm is an early-stage drug discovery and development company dedicated to compound re-profiling. We identify compounds that are on the market or that previously failed to make it to market for commercial reasons and re-purpose them into novel indications in order to address areas of unmet medical need. www.re-pharm.com